Skip to main content
OpenTrials
Completed

NCT Number: NCT05685017

Adiponectin, ICAM-1, VCAM-1 Levels and Metabolic Syndrome in Obese Adolescents

Adipose tissue secreting a number of adipokines which regulate insulin sensitivity, energy metabolism and vascular homeostasis, so the dysfunction of adipose tissue is linked with the incidence of obesity accompanied with insulin resistance, hypertension and cardiovascular disease (1). Obesity is known to alters the expression of adipokines due to the adipose tissue hypertrophy (2), including adiponectin, in which able to exert a potent anti-inflammatory and vascular protective effect (2).

It has been proposed that adiponectin acts to prevent the vascular dysfunction due to obesity and diabetes by improves insulin sensitivity and metabolic profiles to reduce the risk factors for cardiovascular disease and protects the vasculature through its pleiotropic actions on endothelial cells, endothelial progenitor cells, smooth muscle cells and macrophages (1). The concentrations of adiponectin of 5 to 25 mg/mL had a significant inhibitory effect on the expression of monocyte adhesion and adhesion molecule induced by TNF-α in vitro. Atherosclerosis is an inflammatory disease in which adhesion molecules on arterial endothelial cells are responsible for the accumulation of monocytes/macrophages and T lymphocytes. While obesity is low-grade inflammation in which make a contribution on endothelial dysfunction by increasing the oxygen-derived free radicals (ROS) due to adipocyte hypertrophy, leads to an endoplasmic reticulum (ER) stress and mitochondrial dysfunction (3). Adiponectin is accumulated in the vasculature, and it reduced on obesity due to suppression by TNF-α and lead to adiponectin-deficiency which stimulate the significant increases of Vascular cell adhesion protein 1 (VCAM-1) and Intercellular Adhesion Molecule 1 (ICAM-1) or known as CD54 in aortic intima (4).

Here we investigate the level of adiponectin, ICAM-1, VCAM-1 with the incidence of MetS in obese adolescents.

Completed

Looking for future studies?

Notify Me

Key information

About this study

A cross sectional study with healthy obese adolescents aged 13 until 18 years old were conducted during October 2019 to January 2020. Obesity was determined based on body mass index (BMI) for age based on gender > percentile 95th of CDC growth chart 2000.

Body weight was measured using Seca Robusta 813 digital scale in standing position, by stepping on the scale. While Body height was measured using Seca 206 Body Meter. Height was measured from the vertex of the head to the heel in standing position. Waist circumference and hip circumference were measured using Seca 201 measuring tape. Waist circumference was measured by wrapping the measuring tape around the subject's stomach, at the midpoint between the lowest rib and the endpoint of the iliac crest upon expiration, in line with the navel. Hip circumference was measured by asking the subjects to keep the feet together, then wrapping the measuring tape around the widest part of hips, at the point of the greatest gluteal protuberance. The subjects were measured using light cloth without food wear and other accessories such as belt, hat, or hair accessories, etc.

Blood pressure was measure using Omron Automatic Blood Pressure Monitor HEM-8712 (Omron Health Care Co., Ltd, Japan) by placing the cuff on the right arm, then pull and tighten it according to the size if the arm. After it was installed correctly (fasten and did not move), the power button on the digital tension tool was pressed, and then the microprocessor started to drive air pressure into the cuff, and then the value of blood pressures will appear in the manometer tube column.

Metabolic syndrome criteria were determined using The International Diabetic Federation criteria18:

  • For adolescent aged 10-16 years old: if there was a central obesity (waist circumference > 90th percentile based on WHO waist circumference table. For boys at the circumference of > 88 cm, and ≥ 85 cm for girls) accompanied with at least 2 other signs below:
  • Blood pressure > 90th percentile (systole ≥130/diastole ≥ 85 mmHg).
  • Hypertriglyceridemia, if the triglyceride levels > 110 mg/dl.
  • Low level HDL-c, if the HDL-c levels < 40 mg/dl, and < 50 mg/dl for girls.
  • Hyperglycaemia, if fasting blood glucose (FBG) levels was > 110 mg/dl.
  • For adolescent aged more than 16 years old: if there was a central obesity (waist circumference > 90th percentile based on WHO waist circumference table. For boys at the circumference of > 94 cm, and ≥ 80 cm for girls) accompanied with at least 2 other signs below:
  • Blood pressure > 90th percentile (systole ≥130/diastole ≥ 85 mmHg).
  • Hypertriglyceridemia, if the triglyceride levels ≥ 150 mg/dl.
  • Low level HDL-c, if the HDL-c levels <40 mg/dl for boys, and < 50 mg/dl for girls.
  • Hyperglycaemia, if fasting blood glucose (FBG) levels was ≥ 100 mg/dl19. Blood samples were withdrawn via vena cubitus as much as 5 ml by the trained analysts, and placed on vacutainer with EDTA. After that, the vacutainer was replaced in icebox to transport to the laboratory. Blood analysis include: lipid profile, fasting blood glucose, fasting insulin and adiponectin using the ELISA method in the laboratory. Intercellular Adhesion Molecule-1 (ICAM-1) was analyzed using Human intercellular adhesion molecule 1 Elisa kit (Bioassay Technology Laboratory). while sVCAM-1 was analysed using Human vascular cell adhesion molecule-1 Elisa kit (Bioassay Technology Laboratory).

Statistical analysis conducted were test of normality and homogeneity test, Anova/ Kruskal-Wallis, Independent sample T-test/Mann-Whitney U test, and Spearman correlation, and determined as significant if p value<0.05.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Obesity
  • Healthy (no medication treatment)

Exclusion criteria

  • Taking corticosteroids or dyslipidemia medication
  • Smoking or drinking (consuming alcohol)
  • Taking antibiotics or hormonal therapy
  • Autoimmune disease
  • Endocrinology disorders

Treatment and study plan

Nur Aisiyah Widjaja

Diagnostic Test

Blood analysis for ICAM-1, VCAM-1, blood fasting insulin, lipid profile, fasting blood glucose and adiponectin investigation

Other names: Suhasta Nova, Leonardo Alexander Caesar

Primary outcomes

  1. ICAM-1 levels

    Time frame: 4 months

    Intercellular Adhesion Molecule 1 also known as CD54 was measured Human intercellular adhesion molecule 1 Elisa kit (Bioassay Technology Laboratory), stated as pg/ml (mean +/- SD)

  2. VCAM-1

    Time frame: 4 months

    Vascular cell adhesion molecule 1 was measured using Human vascular cell adhesion molecule-1 Elisa kit (Bioassay Technology Laboratory), stated as pg/ml (mean +/- SD)

  3. Adiponectin

    Time frame: 4 months

    For Adiponectin, ICAM-1 and VCAM-1 analysis, the blood that has been taken was not immediately analysed. The blood was centrifuged to remove the serum, and then stored at -70°C until the analysis was performed in the laboratory. Adiponectin was analysed using using Human Adiponectin Elisa kit (Bioassay Technology Laboratory), stated as ng/ml (mean +/- SD)

Secondary outcomes

  1. Physical Measurements: Body weight

    Time frame: 4 months

    body weight was measured using Seca Robusta 813 digital scale in standing position by stepping on the scale. The subjects were asked to use light clothes without footwear or accessories. Stated as kg (mean +/- SD)

  2. Physical Measurements: Body height

    Time frame: 4 months

    Body height was measured using Seca 206 Body Meter. Height was measured from the vertex of the head to the heel in standing position without footwear or accessories such as hat

Other outcomes

  1. Physical Measurements: Waist Circumference

    Time frame: 4 months

    Waist circumference was measured by wrapping the measuring tape (Seca 201 measuring tape),around the subject's stomach, at the midpoint between the lowest rib and the endpoint of the iliac crest upon expiration, in line with the navel. Stated as cm (mean +/- SD)

  2. Physical Measurements: Hip Circumference

    Time frame: 4 months

    Hip circumference was measured by asking the subjects to keep the feet together, then wrapping the measuring tape (Seca 201 measuring tape) around the widest part of hips, at the point of the greatest gluteal protuberance, stated as cm (mean +/- SD)

  3. Blood Pressure: Systole and diastole

    Time frame: 4 months

    Blood pressure was measured using Omron Automatic Blood Pressure Monitor HEM-8712, Omron Health Care Co., Ltd, Japan. The cuff was placed on the right arm, then pull and tighten it according to the size if the arm. After it was installed correctly (fasten and did not move), the power button on the digital tension tool was pressed, and then the microprocessor started to drive air pressure into the cuff, and then the value of blood pressures will appear in the manometer tube column. Stated as mmHg (mean +/- SD)

  4. Blood biochemistry: HDL-c levels

    Time frame: 4 months

    The HDL-c levels were analysed by a designated medical laboratory after withdrawn, stated as mg/dl (mean +/- SD)

  5. Blood biochemistry: Triglyceride levels

    Time frame: 4 months

    The triglyceride levels were analysed by a designated medical laboratory after withdrawn, stated as mg/dl (mean +/- SD)

  6. Blood biochemistry: Fasting blood glucose levels

    Time frame: 4 months

    Fasting blood glucose levels were analysed by a designated medical laboratory after withdrawn, stated as mg/dl (mean +/- SD)

  7. Blood biochemistry: Fasting insulin levels

    Time frame: 4 months

    Fasting insulin levels were analysed by a designated medical laboratory after withdrawn, stated as mg/dl (mean +/- SD)

Sponsors and collaborators

Lead sponsor

Universitas Airlangga

Other

Registry information

Acronym: ICAM; VCAM

Important dates

Study start
2019
Primary completion
2020
Study completion
2020
First posted
Jan 13, 2023
Registry last updated
Jan 13, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.